Protocol Ledger

Therapeutic Cohort OPH · ClinicalTrials.gov API v2

Ophthalmology and Sensory: Phase II & III Clinical Trial Benchmarks

Protocol Ledger tracks 936 interventional Phase II and Phase III Ophthalmology and Sensory protocols registered from 2018 through 2026, including 295 active studies, 438 completed studies, and 95 early-stopped studies (10.15% overall; 17.82% of closed trials).

Median Enrollment: 106.0 participants Median Completed Span: 427 days California Share: 317 studies (33.9%)

1. Reconciled Ophthalmology and Sensory Execution & Stop-Cause Profile

Ophthalmology and Sensory Cohort Metrics (Publication 47c4426df7e9d67d5bfe)
Clinical Trial Metric Verified Value Operational Context
Total Phase II & III Protocols (2018 to 2026) 936 Deterministic primary MeSH and condition-keyword assignment
Active Concurrent Pipeline 295 Recruiting, enrolling by invitation, and active follow-up protocols
Completed vs Prematurely Stopped 438 / 95 17.82% closed-trial attrition ratio across 533 closed protocols
Slow Accrual vs Safety & Futility Stops 13 / 11 / 13 Slow accrual (WS1) vs clinical safety (WS4) vs interim futility (WS5)
Physical Hospital Site Disclosure Rate 81.7% Named hospital campus participations vs anonymized CRO site slots

2. Leading Consolidated Trial Sponsors Focused on Ophthalmology and Sensory

Consolidated Biopharma, Academic & Federal Sponsors (Ophthalmology and Sensory Primary Focus)
Sponsor Hub Sector Protocols Active Completed FDA NDA/BLA
Shahid Beheshti University of Medical Sciences Academic / Institutional Sponsor 34 2 5 0
Bausch Health Biopharma Industry 33 4 26 133
Aldeyra Therapeutics Biopharma Industry 29 1 27 0
Apellis Pharmaceuticals Biopharma Industry 19 4 12 0
Dompé Farmaceutici S.p.A Biopharma Industry 19 4 8 0
Glaukos Biopharma Industry 16 5 7 4

3. Representative Multi-Center Phase II & III Ophthalmology and Sensory Studies

Indexed ClinicalTrials.gov v2 Study Dossiers in Ophthalmology and Sensory
NCT Study Protocol Brief Title Sponsor Phase Status
NCT07740564 Phase III Study of OT202 in Treating Moderate to Severe Dry Eye Ocumension Therapeutics (Suzhou) Co Phase III RECRUITING
NCT06997874 Treatment of Retinal Detachment in People Who Have Not Had Cataract Surgery With Vitrectomy vs Vitrectomy and Cataract Removal Queen's University, Belfast Phase III RECRUITING
NCT07317934 Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR) Innostellar Biotherapeutics Co Phase III RECRUITING
NCT06708156 The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression Oupushifang Pharmaceutical Technology Co Phase III RECRUITING
NCT06753916 ExCrossV Multi Site Trial for Vascularized High Risk Keratoplasty Massachusetts Eye and Ear Infirmary Phase II RECRUITING
NCT07567040 Delaying the Onset of Nearsightedness Until Treatment (DONUT) Clinical Trial Ohio State University Phase III RECRUITING
NCT07395232 An Efficacy and Safety Study of DFL24498 in the Treatment of AKC Dompé Farmaceutici S.p.A Phase III RECRUITING
NCT06891443 Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION) Laboratoires Thea Phase III RECRUITING
NCT06847542 A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD Roche / Genentech Phase III RECRUITING
NCT07776522 Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration West China Hospital Phase II RECRUITING
NCT06213649 Parasitic Ulcer Treatment Trial Jeremy Keenan, MD, MPH Phase III RECRUITING
NCT05821959 Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss Eli Lilly and Company Phase III RECRUITING
NCT06659445 Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD ONL Therapeutics Phase II RECRUITING
NCT07519902 An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED Dompé Farmaceutici S.p.A Phase III RECRUITING
NCT07064759 Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration 4D Molecular Therapeutics Phase III RECRUITING
NCT07441642 A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Novartis Phase II RECRUITING

Related Therapeutic Condition Hubs & Crosswalks

Compare adjacent clinical cohorts: Oncology and Hematology · Rare Genetic, Women's Health, and Other · Infectious Disease and Vaccines · Neurology, Psychiatry, and Pain, browse the interactive Hospital & Sponsor Directory, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI